Primary Peritoneal Carcinoma — Trials

Primary Peritoneal Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 92
Recruiting: 35
Ph III recruiting: 5
Growth YoY: —
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (46)

clinicaltrialsPublishedShowing 51–100 of 294 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02650986	Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1	active not recruiting	Phase 1 / Phase 2	15	Roswell Park Cancer InstituteOTHER	1	Jul 8, 2026	clinicaltrials
NCT03587311	Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	Phase 2	96	National Cancer Institute (NCI)NIH	2	Jul 8, 2026